Poster B80: Combination Screening of I/O and Targeted Agents In Vitro

Pharmacological Inhibition of Syngeneic Murine Cancer Cell Proliferation by Checkpoint Inhibitors in Combination with Targeted Agents

Chunlan Dong, Xiaoxi Xu, Qinyun Ma*, Teng Lu, Zhe Sun, Wubin Qian, Sheng Guo, Qian Shi, and Frank Xing
*Fudan University Affiliated Huashan Hospital, Shanghai 200040, China

To advance preclinical immuno-oncology drug discovery, CrownBio has developed a syngeneic model screening platform for evaluating the in vivo efficacy of immuno-oncology agents (MuScreen™, Poster A64).

To allow the combination of clinically promising therapeutic strategies which activate immune cells with targeting the unique genetic characteristics of a tumor model, we thoroughly characterized the mutation profiles of these syngeneic cell lines and examined drug response profiles through in vitro screening.

This work provides an in vitro system for evaluating combination effectiveness when targeting both immune checkpoint markers and oncogenic targets in preclinical studies.

Read this Poster to Discover:

• The development of a fast and cost-efficient in vitro platform to assess immune response to checkpoint inhibitors alone, and in combination with targeted agents.
  
  
• Initial correlation between genomic and pharmacological data.
  
  
• Expansion plans for our in vitro syngeneic mouse cell line panel, to provide informative suggestions toward in vivo MuScreen studies.

Download the Poster Now!